Iterum Therapeutics plc announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer, positioning the company for the upcoming U.S. launch of ORLYNVAH™, its FDA-approved oral antibiotic for treating uncomplicated urinary tract infections caused by multi-drug resistant pathogens.
Leadership Appointment Strengthens Commercial Capabilities
Coyne will lead all commercial efforts for Iterum, including the ORLYNVAH launch and future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. "Her deep expertise across the commercial spectrum—particularly in anti-infectives—will be instrumental as we aim to accelerate launch readiness for ORLYNVAH™ and scale our capabilities for long-term growth."
The appointment brings significant industry experience to Iterum's leadership team. Coyne has more than 30 years of commercial and operational experience in the pharmaceutical industry, most recently serving as Chief Commercial Officer at Innoviva, where she led the development and execution of go-to-market strategies across the company's infectious disease and critical care portfolio.
Extensive Anti-Infective Experience
Prior to Innoviva, Coyne held the role of Chief Commercial Officer at SCYNEXIS, where she successfully led the company's anti-infective portfolio and built its commercial infrastructure from the ground up. Her career also includes senior commercial leadership roles at Paratek Pharmaceuticals, BTG Pharmaceuticals, Auxilium, Endo, and Wyeth/Pfizer.
"I'm honored to join Iterum at such an important moment for both the company and the patients we aim to serve," said Coyne. "The upcoming U.S. launch of ORLYNVAH™ represents a significant opportunity to bring innovation to an area with considerable unmet need, and I look forward to leading the team to deliver a successful launch and position Iterum for sustained growth."
ORLYNVAH Addresses Critical Medical Need
ORLYNVAH is a novel oral penem antibiotic approved by the FDA for the treatment of uncomplicated urinary tract infections caused by designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options. The drug possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins.
The active compound, sulopenem, is a novel penem anti-infective that has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Strategic Partnership for Commercial Launch
Iterum is preparing for the commercial launch with its commercialization partner, EVERSANA, which will support the company in building and maintaining a sales force for the potential commercial launch of ORLYNVAH. The company aims to bring ORLYNVAH to market in the U.S. in the next quarter, representing a significant milestone in addressing the global crisis of multi-drug resistant pathogens.
Coyne holds a Bachelor of Arts from West Chester University and a Master of Business Administration from Eastern University, bringing both academic credentials and extensive practical experience to her new role at Iterum.
